

S 4867

Accelerating Access to Critical Therapies for ALS Act

Congress: 116 (2019–2021, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Oct 26, 2020

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Oct 26, 2020)

Official Text: <https://www.congress.gov/bill/116th-congress/senate-bill/4867>

Sponsor

Name: Sen. Coons, Christopher A. [D-DE]

Party: Democratic • State: DE • Chamber: Senate

Cosponsors (15 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Murkowski, Lisa [R-AK]	R · AK		Oct 26, 2020
Sen. Boozman, John [R-AR]	R · AR		Nov 30, 2020
Sen. Shaheen, Jeanne [D-NH]	D · NH		Nov 30, 2020
Sen. Capito, Shelley Moore [R-WV]	R · WV		Dec 3, 2020
Sen. King, Angus S., Jr. [I-ME]	I · ME		Dec 3, 2020
Sen. Gillibrand, Kirsten E. [D-NY]	D · NY		Dec 10, 2020
Sen. Loeffler, Kelly [R-GA]	R · GA		Dec 10, 2020
Sen. Cramer, Kevin [R-ND]	R · ND		Dec 16, 2020
Sen. Feinstein, Dianne [D-CA]	D · CA		Dec 16, 2020
Sen. Hoeven, John [R-ND]	R · ND		Dec 21, 2020
Sen. Jones, Doug [D-AL]	D · AL		Dec 21, 2020
Sen. Leahy, Patrick J. [D-VT]	D · VT		Dec 21, 2020
Sen. Manchin, Joe, III [D-WV]	D · WV		Dec 21, 2020
Sen. Moran, Jerry [R-KS]	R · KS		Dec 30, 2020
Sen. Sinema, Kyrsten [D-AZ]	D · AZ		Dec 30, 2020

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Oct 26, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Oct 26, 2020)

Accelerating Access to Critical Therapies for ALS Act

This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions.

The Department of Health and Human Services (HHS) shall award grants to eligible entities to support research on and facilitate access to investigational drugs that diagnose or treat ALS. The Food and Drug Administration shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other severely debilitating neurodegenerative diseases.

HHS shall also establish the Collaborative for Neurodegenerative Diseases, which shall support the development and regulatory approval of drugs that address ALS and other rare neurodegenerative diseases.

Actions Timeline

- **Oct 26, 2020:** Introduced in Senate
- **Oct 26, 2020:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.